Clinical Trial Update: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating olutasidenib for drug-drug interaction in IDH1-mutant malignancies. The study is currently recruiting in AML, glioma, cholangiocarcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Cholangiocarcinoma
• Glioma
• Solid Tumors

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Status: RECRUITING